Serum Soluble RANKL (sRANKL)
Transmembrane and shed cytokine (TNFSF11) expressed by osteoblasts and activated T-lymphocytes that drives osteoclast differentiation and activation.
Standard vs. Optimal Reference Rangespmol/L
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
0.1 - 0.9 pmol/L
General reference distribution across unselected commercial populations.
<0.4 pmol/L
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Binds the RANK receptor on osteoclast precursor membranes, triggering NF-kB and NFATc1 transcription factors to promote osteoclastogenesis.
Differential Diagnosis
Elevated Levels (sRANKL High)
- •High osteoclastogenesis and accelerated bone resorption
- •Osteolytic bone metastases and giant cell tumors
- •Rheumatoid synovial joint destruction
Low Levels (sRANKL Low)
- •Suppressed osteoclastogenesis (Denosumab target <0.1 pmol/L)
- •Low-turnover bone state
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for sRANKL
- Targeted organ system imaging or functional dynamic testing related to osteoclast differentiation factor
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Serum Soluble RANKL - The New England Journal of Medicine (2021). PMID: 34190124
- [2]sRANKL Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35422901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Serum Soluble RANKL (sRANKL) into overall healthspan optimization.